

AmoyDx® HANDLE OncoPro Panels

Comprehensive Tumor Profiling, Now with Flexible Options

Flexible Panel Versions Meet Diverse Laboratory Needs

AmoyDx® HANDLE OncoPro Compact NGS Panel	AmoyDx® HANDLE OncoPro NGS Panel
This core assay delivers extensive analysis of 195 pan-tumor genes and MSI status.	This includes every feature of the Compact panel plus integrated HRD status assessment

In-house Multi-biomarker Testing with Extensive Coverage of Solid Tumors

Non-Small Cell Lung Cancer	Colorectal Cancer	Breast Cancer	Prostate Cancer	Glioma	Stomach Cancer	Thyroid Cancer	Ovarian Cancer
EGFR ALK MET BRAF ROS1 NTRK1/2/3 RET KRAS ERBB2 (HER2)	KRAS NRAS MSI BRAF ERBB2 (HER2) NTRK fusion RET fusion PIK3CA POLE POLD1	BRCA1 BRCA2 ERBB2 PIK3CA PTEN AKT1 ESR1 NTRK fusion RET fusion	ATM ATR BARD1 BRCA1 BRCA2 BRIP1 CDK12 CHEK1 CHEK2 FANCA FANCL MLH1 MRE11 NBN PALB2 RAD51B RAD51C RAD51D RAD54L PTEN PIK3CA AKT1 MSI	IDH1/2 ATRX TERT promoter H3-3A H3C2 BRAF ZFTA fusion MYCN amplification CDKN2A/B HD EGFR	ERBB2 (HER2) MSI NTRK1/2/3 RET BRAF EBV Status	KRAS NRAS BRAF RET NTRK pTERT	BRCA1 BRCA2 HRD Status* ERBB2 (HER2) BRAF RET NTRK1/2/3

Note: The listed biomarkers are key examples covered in the panel and do not represent the full list.

*HRD status assessment is available exclusively with the AmoyDx® HANDLE OncoPro NGS Panel.

Comprehensive Tumor Profiling Made Simple



All-in-One, Pan-Tumor Solutions

- **195 pan-solid-tumor genes:** all guideline-recommended and emerging biomarkers across lung, colorectal, breast, prostate, ovarian, glioma, gastric, thyroid cancers, and more.
- SNV, InDel, CNV, HD, MSI (DNA level) and Fusions, MET exon 14 skipping (RNA level)



Highlighted Advanced Biomarkers

- **Homozygous Deletions (HDs):** HD detection with proprietary algorithm in 26 key genes, including MTAP – a novel target for PRMT5 inhibitors.
- **HRR Gene Mutations (HRRm):** Covers all key HRR genes associated with FDA-approved PARPis (Olaparib, Rucaparib, Niraparib, Talazoparib).
- **Microsatellite Instability (MSI) Status:** Both panels provide robust MSI status assessment, offering extended insights for management strategies.
- **Optional HRD Status:** The AmoyDx® HANDLE OncoPro NGS Panel adds integrated Homologous Recombination Deficiency (HRD) status assessment for deeper insights into genomic instability.




Comprehensive Tumor Profiling Powered by HANDLE

- Decentralized and cost-effective solution, making in-house tumor profiling accessible
- Streamlined workflow with one-tube operations
- < 1 hour hands-on time, < 6 hours total library preparation with 3-day turnaround time


Making Complex NGS Testing Easy to HANDLE

Innovative NGS technology: Halo-shape ANnealing and Defer-Ligation Enrichment (HANDLE)



- Turnaround time (TAT) from sample to report: within 3 days
- Easy workflow and low cost, as simple as PCR assay
- One-tube, hands-on time < 1 hour, total library construction time < 6 hours

Streamlined Workflow from Sample to Report in 3 days



Ordering Information

Panel Name	AmoyDx® HANDLE OncoPro Compact NGS Panel	AmoyDx® HANDLE OncoPro NGS Panel
Catalog Number	8.06.0209	8.06.0186
Panel Coverage	195 genes plus MSI	195 genes plus MSI, HRD
Kit Format	24 tests/kit	
Instrument	Illumina NextSeq 500, NextSeq 550, NextSeq 550Dx	
Storage & Shelf-life	-25°C to -15°C for 12 months	

For Research Use Only. Not for use in diagnostic procedures.

E-mail: info@amoydx.com

Address: 2 Science Park Drive, Ascent #01-08, Singapore 118222

©2024 AmoyDx, All rights reserved.



F251801